Prime-boost vaccination using influenza A H5N1 vaccines

使用甲型 H5N1 流感疫苗进行初免加强接种

• 批准号: G0600846/1
• 负责人: Karl Nicholson
• 金额: $ 125.4万
• 依托单位: University of Leicester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0600846%2F1
• 关键词: Prime; boost; vaccination; using; influenza

Vaccination offers the best method for protecting the general population against an influenza pandemic, but has limitations. The output from the vaccine industry will be insufficient to meet demand, and the time required to make a pandemic vaccine means that it will be scarce and possibly unavailable during the first wave of the pandemic. The new, deadly H5N1 influenza virus, when given as an ordinary vaccine, is also very poor at stimulating protective antibody responses. Our study explores the possibility of ?priming? people with small quantities of an H5 adjuvanted vaccine (which contains a substance to enhance the body?s immune response) before a pandemic with the expectation that the body will develop a more vigorous immune response to a pandemic vaccine when it became available. This would enable scarce supplies of pandemic vaccine to be given more efficiently, with protection of more people more rapidly

疫苗接种是保护普通人群免受流感大流行的最佳方法，但也有局限性。疫苗行业的产量将不足以满足需求，而制造大流行疫苗所需的时间意味着疫苗将很稀缺，在大流行的第一波期间可能无法获得。新的致命的H5N1流感病毒，当作为普通疫苗接种时，在刺激保护性抗体反应方面也非常差。我们的研究探讨了？启动？服用少量H5佐剂疫苗（含有增强体质的物质？在流感大流行之前，人们期望身体会对流感疫苗产生更强烈的免疫反应。这将使稀缺的大流行疫苗供应能够更有效地提供，更迅速地保护更多的人